Cantargia AB (publ) CANTA
Updated: 11 Jun 2026
No signal published yet
We already track Cantargia and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Cantargia AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Cantargia free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 11, 2026, Cantargia announced a KOL call to discuss nadunolimab's role in pancreatic cancer following the start of a Phase 2 lung cancer prevention study on June 10. The company also recently launched a 124 MSEK rights issue and secured a 75 MSEK loan facility to support its clinical programs.
What Firelda Watch includes for Cantargia AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Cantargia AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Cantargia free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more